Should women be screened for ovarian cancer?
We hope to answer this question with the Ovarian Cancer Low Risk Study. About 25,000 women in the U.S. are diagnosed with ovarian cancer each year. Most don’t have any symptoms until the disease is advanced. Currently, MD Anderson does not recommend routine screening for ovarian cancer.
Are there ovarian cancer screening tests available?
Currently, there are no effective tests to detect ovarian cancer at its earliest stages, but if ovarian cancer is found early, the chances of cure increase dramatically. MD Anderson researchers hope this study will result in more effective ovarian cancer screening methods.
What is the purpose of this study?
MD Anderson researchers are evaluating a blood (CA-125) test that may be helpful in the early detection of ovarian cancer in healthy, post-menopausal women.
Here’s how it works.
- conduct a telephone interview with you
- perform a blood test (annually or quarterly)
- request that you complete a medical history questionnaire
- perform a transvaginal ultrasound (for some, but not all participants)
Am I eligible?
You’re eligible to participate if you:
- are between the ages of 50 and 74
- are post-menopausal (no period for one year or longer)
- have not received cancer treatment for at least 12 months
What are the benefits of participating?
- receive ovarian cancer screening tests at no cost
- contribute valuable information to medical research which may benefit future generations
How do I find out more or enroll?
Currently our study is available in Florida, Iowa, New Jersey, New York, Oklahoma, Rhode Island and Texas. Participants will need to travel to one of these locations below for the blood test and transvaginal ultrasound if needed. We will continue to add more sites, so please refer back to this webpage for updates.
Please call or email one of the contacts below and ask how you can become a participant in the Low Risk Ovarian Study ID01-022.
Sylvester Comprehensive Cancer Center/UMHC
1475 N.W. 12th Ave.
Miami, FL 33136
Contact: Karen Dimentstein
John Stoddard Cancer Center/Unity Point Health
1221 Pleasant St.
Des Moines, IA 50309
Contact: Pati Berger, RN, BSN, OCN
Stephenson Cancer Center /University of Oklahoma Health Sciences Center
800 N.E. 10th Street, Suite 5050
Oklahoma City, OK 73104
Contact #1: Cathy Birdsong
Office: 405-271-8001 x48715
Contact #2: Sarah Cooper
Office: 405-271-8001 x53481
Carol G. Simon Cancer Center / Atlantic Health Morristown Memorial Hospital
100 Madison Ave.
Morristown, NJ 07962
Contact: Maria Bell
URMC-Center for Community Health
46 Prince Street
Rochester, NY 14607
Contact #1: Kaitlyn Burrows
Contact #2: Candice A. Lucas
Woman & Infants Hospital
45 Willard Ave.
Providence, RI 02905
Contact: Cindy Brizard
Office: 401-274-1122 x48190
The University of Texas MD Anderson Cancer Center
1400 Pressler St.
Houston, Texas 77030
Contact: Alexis Perez, CMA
Women’s Hospital of Texas (OGA)
7900 Fannin St.
Houston, TX 77054
Contact: Samantha Trevino
UT Southwestern Medical Center
5323 Harry Hines Blvd.
Dallas, TX 75390
Contact #1: Isabel Villalobos, M.S.
Contact #2: Tiffany Thomas
Who are the specialists involved in this study?
Karen H. Lu, M.D., is the study chair for the Low Risk Ovarian Cancer Study
Will my information be kept confidential?
All information that you provide, as well as your blood sample results, will be completely confidential. No one outside this study may have access to your information without your permission.